CANbridge Pharma Overview
- Founded
- 2012
- Status
- Private
- Latest Deal Type
- Series E
- Latest Deal Amount
- $43M
- Investors
- 20
CANbridge Pharma General Information
Description
Developer of innovative biological drugs designed to treat critical medical conditions. The company's specialty healthcare products prevent and treat high-profile oral mucositis, breast cancer, genetic diseases, and other chronic diseases, enabling patients to access improved treatment.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
- Suite 301,3F,Timeloit, No. 17 RongChuang Road
- Chaoyang District
- Beijing
- China
+86 010 0000 0000
CANbridge Pharma Timeline
CANbridge Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series E) | 01-Dec-2020 | $43M | 00000 | Completed | Generating Revenue | |
| 5. Later Stage VC | 04-Sep-2020 | 00000 | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series D) | 18-Feb-2020 | 0000 | 00000 | Completed | Generating Revenue | |
| 3. Later Stage VC (Series C) | 01-Apr-2019 | 0000 | 0000 | 00000 | Completed | Generating Revenue |
| 2. Early Stage VC (Series B) | 24-May-2017 | $25M | $35M | 0000 | Completed | Startup |
| 1. Early Stage VC (Series A) | 03-Dec-2014 | $10M | $10M | 0000 | Completed | Startup |
CANbridge Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of innovative biological drugs designed to treat critical medical conditions. The company's specialty healthca
Pharmaceuticals
Beijing, China
00000
00000000000
00000
00000000
e irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
0000000000000
San Francisco, CA
000
As of 0000
00000
0.000
0000-00-00
000000&0
00000
0000000
te velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident
0000 000000000
Shanghai, China
000
As of 0000
00000
00000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialCANbridge Pharma Competitors (43)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Principia Biopharma | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Shanghai, China | 000 | 00000 | 00000000000 | 00000 |
| 0000 00000000000 | Venture Capital-Backed | Shanghai, China | 00000 | 00000000000 | 00000 | |
| 000000000 | Formerly VC-backed | South San Francisco, CA | 00000 | 000.00 | 00000000000 | |
| 0000000 | Formerly PE-Backed | Beijing, China | 0000 | 00.000 | 000000000 | 00.000 |
CANbridge Pharma Executive Team (14)
CANbridge Pharma Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Guangping Gao Ph.D | CANbridge Pharma | Board Member | 000 0000 |
| James Xue Ph.D | CANbridge Pharma | Founder, Chief Executive Officer and Chairman | 000 0000 |
| Mark Bamforth | CANbridge Pharma | Board Member | 000 0000 |
| Xubo Hu | Qiming Venture Partners | Board Member | 000 0000 |
CANbridge Pharma Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| 3W Partners Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Casdin Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| LYFE Capital | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| SPDB International | Corporation | Minority | 000 0000 | 000000 0 | |
| Summer Capital | Venture Capital | Minority | 000 0000 | 000000 0 |